

CLAIMS

1. An agent for the prevention and/or treatment of Alzheimer's disease containing c-Abl and/or p19^{ARF} as (an) active ingredient(s).

2. A screening method wherein a candidate drug which inhibits the interaction between AICD and p53 in neurons is selected as a drug for the prevention and/or treatment of Alzheimer's disease.

3. A screening method wherein a candidate drug which inhibits the interaction between AICD and p53 in neurons is selected as a drug for the prevention and/or treatment of Alzheimer's disease, said screening method comprising:

a step of culturing neurons expressing AICD and p53 in which an AICD/p53 complex is formed, together with a candidate drug;

a step of obtaining a first immune complex which is a complex of AICD or p53 with a first antibody selected from an anti-AICD antibody and an anti-p53 antibody, and a second immune complex which is a complex of the AICD/p53 complex with the first antibody, by bringing a cell lysate prepared from the cultured neurons in contact with the first antibody;

a step of bringing the first and second immune complexes in contact with a second antibody which is selected from an anti-AICD antibody and an anti-p53 antibody, and which is different from the first antibody; and

a step of detecting the presence of a third immune complex which is a complex of the second immune complex with the second antibody.

4. An agent for the prevention and/or treatment of Alzheimer's

disease containing AICD as an active ingredient.

5 5. An agent for the prevention and/or treatment of Alzheimer's disease containing a peptide which comprises the amino acid sequence set forth in SEQ ID NO: 1 or 2 of the Sequence Listing as an active ingredient.

6. A screening method wherein a candidate drug which inhibits the interaction between AICD and Fe65 in neurons is selected as a drug for the prevention and/or treatment of Alzheimer's disease.

10 7. A screening method wherein a candidate drug which inhibits the interaction between AICD and Fe65 in neurons is selected as a drug for the prevention and/or treatment of Alzheimer's disease, said screening method comprising:

 a step of culturing neurons expressing AICD and Fe65 in which an AICD/Fe65 complex is formed, together with a candidate drug;

15 a step of obtaining a first immune complex which is a complex of AICD or Fe65 with a first antibody selected from an anti-AICD antibody and an anti-Fe65 antibody, and a second immune complex which is a complex of the AICD/Fe65 complex with the first antibody, by bringing a cell lysate prepared from the cultured neurons in contact
20 with the first antibody;

 a step of bringing the first and second immune complexes in contact with a second antibody which is selected from an anti-AICD antibody and an anti-Fe65 antibody, and which is different from the first antibody; and

25 a step of detecting the presence of a third immune complex which is a complex of the second immune complex with the second

antibody.

8. A screening method wherein a candidate drug which inhibits the interaction between AICD and Tip60 in neurons is selected as a drug for the prevention and/or treatment of Alzheimer's disease.

5 9. A screening method wherein a candidate drug which inhibits the interaction between AICD and Tip60 in neurons is selected as a drug for the prevention and/or treatment of Alzheimer's disease, said screening method comprising:

10 a step of culturing neurons expressing AICD and Tip60 in which an AICD/Tip60 complex is formed, together with a candidate drug;

a step of obtaining a first immune complex which is a complex of AICD or Tip60 with a first antibody selected from an anti-AICD antibody and an anti-Tip60 antibody, and a second immune complex which is a complex of the AICD/Tip60 complex with the first antibody, by bringing a cell lysate prepared from the cultured neurons in contact with the first antibody;

15 a step of bringing the first and second immune complexes in contact with a second antibody which is selected from an anti-AICD antibody and an anti-Tip60 antibody, and which is different from the first antibody; and

20 a step of detecting the presence of a third immune complex which is a complex of the second immune complex with the second antibody.

25 10. A drug for the prevention and/or treatment of Alzheimer's disease which can be obtained by the screening method according to claim 3, 7 or 9.